Rhythm Pharmaceuticals (RYTM) Reports Late-breaking Data from Ph 3 Trials of Setmelanotide in POMC & LEPR Deficiency Obesities

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. GOOGL
6. APGE
7. HOOD
8. DFTX
9. MU
10. IBM

Go back to Rhythm Pharmaceuticals (RYTM) Reports Late-breaking Data from Ph 3 Trials of Setmelanotide in POMC & LEPR Deficiency Obesities

Rhythm Pharmaceuticals (RYTM) Tops Q3 EPS by 3c

November 1, 2019 8:36 AM EDT

Rhythm Pharmaceuticals (NASDAQ: RYTM) reported Q3 EPS of ($1.04), $0.03 better than the analyst estimate of ($1.07).

Announced Positive Topline Results from Pivotal Phase 3 Clinical Trials Evaluating Setmelanotide in POMC and LEPR Deficiency ObesitiesAdded Four New MC4R Pathway Obesity Indications to Phase 2 Basket Study and Enrolling Patients --Announced Genetic Sequencing Data Supporting Ultra-Rarity of POMC and LEPR Deficiency Obesities and Suggesting U.S. Prevalence for Four New Basket Indications of > 60,000Successfully Completed $172.5 Million Public... More